Mepenzolate bromidemAchR antagonist, working as a post-ganglionic parasympathetic inhibitor to decrease gastric acid and pepsin secretion and suppresse spontaneous contractions of the colon.
Mepenzolate bromide (MP), an antagonist for human muscarinic M3 receptor (hM3R), has both anti-inflammatory and short-acting bronchodilatory activities[3]. Mepenzolate bromide, used to treat gastrointestinal disorders in clinical settings, also displayed beneficial effects in chronic obstructive pulmonary disease and pulmonary fibrosis of a mouse model by inhibiting inflammatory responses and reducing oxidative stress[4]. Apart from suppressing elastase-induced pulmonary inflammatory responses and the production of superoxide anions, mepenzolate bromide reduces the level of cigarette smoke-induced airspace enlargement and respiratory dysfunction. Mpenzolate bromide may be an effective therapeutic for the treatment of COPD (chronic obstructive pulmonary disease) due to its anti-inflammatory and bronchodilatory activities[5]. The intratracheal administration of mepenzolate reduced bleomycin-induced pulmonary fibrosis and lung dysfunction in mice[6].
搜索
